Meeting
2018 ASCO Annual Meeting
A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients with metastatic melanoma.
Authors
Amod Sarnaik
Moffitt Cancer Center, Tampa, FL
Amod Sarnaik , Brendan D. Curti , Diwakar Davar , John M. Kirkwood , Omid Hamid , Jose Lutzky , Melissa Wilson , Harriet M. Kluger , Eric D. Whitman , Giao Q. Phan , Sajeve Samuel Thomas , Karl D. Lewis , Hendrik-Tobias Arkenau , Jason Alan Chesney , Bente Larsen , Igor Gorbatchevsky , Sam Suzuki , Nancy Louise Samberg , Maria Fardis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02360579
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS9595)
DOI
10.1200/JCO.2018.36.15_suppl.TPS9595
Abstract #
TPS9595
Poster Bd #
422a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.
First Author: Amod Sarnaik
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy.
First Author: Amod Sarnaik
Poster
2023 ASCO Annual Meeting
A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.
First Author: Daniel Olson
Poster
2019 ASCO Annual Meeting
Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.
First Author: Amir A. Jazaeri